MRC1 and colorectal carcinoma: It is interesting to note that we observed a statistically significant difference in survival between “Met-ICI” vs. “ICI” in the overall ICI cohort of CRC patients treated with “Met-ICI” vs. “ICI” with undetermined MMR/MSI status (Figure S2).